During the past decade, Istituto Europeo di Oncologia conducted 326 clinical trials. In the 10-year time frame, 326 clinical trials started and 119 clinical trials were completed, i.e. on average, 36.5% percent of trials that started reached the finish line to date. In the past 5 years, 159 clinical trials started and 80 clinical trials were completed. i.e. 50.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istituto Europeo di Oncologia" #1 sponsor was "Hoffmann-La Roche" with 63 trials, followed by "European Institute of Oncology" with 45 trials sponsored, "Pfizer" with 21 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 20 trials sponsored and "ETOP IBCSG Partners Foundation" with 20 trials sponsored. Other sponsors include 328 different institutions and companies that sponsored additional 162 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Europeo di Oncologia" #1 collaborator was "Merck Sharp & Dohme LLC" with 14 trials as a collaborator, "AstraZeneca" with 13 trials as a collaborator, "Breast International Group" with 12 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 9 trials as a collaborator and "Hoffmann-La Roche" with 8 trials as a collaborator. Other collaborators include 274 different institutions and companies that were collaborators in the rest 195 trials.

According to Clinical.Site data, the most researched conditions in "Istituto Europeo di Oncologia" are "Breast Cancer" (52 trials), "Ovarian Cancer" (26 trials), "Melanoma" (17 trials), "Non-small Cell Lung Cancer" (15 trials) and "Carcinoma, Non-Small-Cell Lung" (13 trials). Many other conditions were trialed in "Istituto Europeo di Oncologia" in a lesser frequency.

Most popular intervention types in "Istituto Europeo di Oncologia" are "Drug" (398 trials), "Other" (43 trials), "Procedure" (39 trials), "Biological" (36 trials) and "Radiation" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "Atezolizumab" (32 trials), "Carboplatin" (28 trials), "Paclitaxel" (26 trials) and "Gemcitabine" (22 trials). Other intervention names were less common.

The vast majority of trials in "Istituto Europeo di Oncologia" are 360 trials for "All" genders, 118 trials for "Female" genders and 22 trials for "Male" genders.

Currently, there are 220 active trials in "Istituto Europeo di Oncologia". 1 are not yet recruiting, 107 are recruiting, 111 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 185 completed trials in Istituto Europeo di Oncologia, 3 suspended trials, and 50 terminated clinical trials to date.

Out of the total trials that were conducted in Istituto Europeo di Oncologia, 60 "Phase 1" clinical trials were conducted, 181 "Phase 2" clinical trials and 215 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 35 trials that are defined as “Not Applicable".

Istituto Europeo di Oncologia has several departments that took part in Clinical trials: "Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (" - 6 trials, "Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica" - 4 trials, "Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di Oncoematologia" - 3 trials, "Istituto Europeo di Oncologia - Divisione di Oncologia Toracica" - 3 trials, "Istituto Europeo di Oncologia Servizio Radioterapia" - 2 trials